<DOC>
	<DOC>NCT01609179</DOC>
	<brief_summary>A treatment protocol that enables patients to have continued access to IPI-926.</brief_summary>
	<brief_title>IPI-926 Extension Protocol for Continuation of Treatment With IPI-926</brief_title>
	<detailed_description>The extension protocol is a continuation of treatment with IPI-926, as administered to each individual patient during participation in their original IPI-926 protocol. Patients who are completing their participation in the original IPI-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with IPI-926 in the extension protocol.</detailed_description>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Veratrum Alkaloids</mesh_term>
	<criteria>1. Voluntarily sign the informed consent form 2. Currently receiving IPI926 while participating in an Infinitysponsored IPI926 study. Note: For blinded studies, patient's treatment assignment must be unblinded according to the instructions in the original protocol to confirm they are receiving IPI926. 3. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. 4. Documented response or stable disease, as defined in the original protocol, at the time of entry to the extension study. 5. Willingness and ability to continue IPI926 dispensation and followup procedures at the current investigational site. 6. Willingness and ability to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures. 7. Women of childbearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. All WCBP, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study. 1. Discontinued IPI926 or withdrew informed consent to participate in original Infinitysponsored IPI926 study. 2. Require addition of or change to a new concomitant therapy to adequately treat the malignancy under study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>